Gilead - Truenewj

Gilead acquires CAR-T specialist Arcellx for .8 billion

Gilead acquires CAR-T specialist Arcellx for $7.8 billion

amefika3 months ago04 mins

Gilead agreed to acquire Arcellx in a deal worth $7.8 billion, as the drugmaker looks to add a CAR T-cell therapy for the treatment of blood cancer that is nearing approval to its portfolio. Under the agreement, Gilead will pay $115 per share, as well as a contingent value right of $5 each. The deal…

Morgan Stanley Expects Gilead Sciences (GILD) to Prosper as Biopharma Policy Uncertainties Dissipate in 2026

amefika5 months ago02 mins

Gilead Sciences Inc. (NASDAQ:BROWN) is one of the best stocks for the next decade. On Dec. 12, Morgan Stanley raised the company’s price target for Gilead to $151 from $147 with an Overweight rating on the stock. The company informed investors that the regulatory and political uncertainties currently weighing on the biopharmaceutical are expected to…